Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals

Cambridge, UK, 2 May 2019 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody® therapeutics, has been granted European patent EP3245226B1.

The patent covers methods for designing libraries for optimised immunoglobulins from transgenic animals.

-Ends-

For more information, please contact:

Crescendo Biologics
+ 44 (0)1223 497140
info@crescendobiologics.com

Instinctif Partners
Melanie Toyne-Sewell, Dr Christelle Kerouedan, Deborah Bell
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics
Crescendo Biologics is a T-cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T-cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA bispecific for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment – avoiding systemic toxicity.

The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V\text{H}). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com.